HomeCompareONCT vs BTI

ONCT vs BTI: Dividend Comparison 2026

ONCT yields 379.79% · BTI yields 5.38%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ONCT wins by $7846.55M in total portfolio value
10 years
ONCT
ONCT
● Live price
379.79%
Share price
$0.53
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$7846.59M
Annual income
$5,169,197,450.71
Full ONCT calculator →
BTI
BTI
● Live price
5.38%
Share price
$58.47
Annual div
$3.15
5Y div CAGR
11.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$37.7K
Annual income
$2,786.64
Full BTI calculator →

Portfolio growth — ONCT vs BTI

📍 ONCT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodONCTBTI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ONCT + BTI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ONCT pays
BTI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ONCT
Annual income on $10K today (after 15% tax)
$32,282.57/yr
After 10yr DRIP, annual income (after tax)
$4,393,817,833.10/yr
BTI
Annual income on $10K today (after 15% tax)
$457.40/yr
After 10yr DRIP, annual income (after tax)
$2,368.64/yr
At 15% tax rate, ONCT beats the other by $4,393,815,464.46/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ONCT + BTI for your $10,000?

ONCT: 50%BTI: 50%
100% BTI50/50100% ONCT
Portfolio after 10yr
$3923.31M
Annual income
$2,584,600,118.67/yr
Blended yield
65.88%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BTI right now

ONCT
Analyst Ratings
4
Buy
3
Hold
Consensus: Buy
Price Target
$28.00
+5217.1% upside vs current
Range: $28.00 — $28.00
Altman Z
-28.6
Piotroski
2/9
BTI
Analyst Ratings
12
Buy
4
Hold
2
Sell
Consensus: Buy
Price Target
$40.00
-31.6% upside vs current
Range: $40.00 — $40.00
Altman Z
2.1
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ONCT buys
0
BTI buys
0
No recent congressional trades found for ONCT or BTI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricONCTBTI
Forward yield379.79%5.38%
Annual dividend / share$2.00$3.15
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%11.3%
Portfolio after 10y$7846.59M$37.7K
Annual income after 10y$5,169,197,450.71$2,786.64
Total dividends collected$7596.65M$14.3K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyBuy
Analyst price target$28.00$40.00

Year-by-year: ONCT vs BTI ($10,000, DRIP)

YearONCT PortfolioONCT Income/yrBTI PortfolioBTI Income/yrGap
1← crossover$48,679$37,979.49$11,299$598.92+$37.4KONCT
2$224,874$172,787.13$12,794$703.91+$212.1KONCT
3$986,585$745,969.70$14,518$829.07+$972.1KONCT
4$4,114,314$3,058,668.09$16,513$978.64+$4.10MONCT
5$16,323,283$11,920,966.77$18,827$1,157.84+$16.30MONCT
6$61,667,489$44,201,576.55$21,518$1,373.12+$61.65MONCT
7$222,048,216$156,064,002.73$24,657$1,632.46+$222.02MONCT
8$762,773,776$525,182,185.09$28,329$1,945.74+$762.75MONCT
9$2,502,234,339$1,686,066,398.09$32,637$2,325.33+$2502.20MONCT
10$7,846,588,193$5,169,197,450.71$37,708$2,786.64+$7846.55MONCT

ONCT vs BTI: Complete Analysis 2026

ONCTStock

Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T) product candidate that targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. Oncternal Therapeutics, Inc. has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. has a research collaboration with Celularity Inc. to evaluate placental derived-cellular therapies targeting ROR1. The company is headquartered in San Diego, California.

Full ONCT Calculator →

BTIConsumer Staples

British American Tobacco p.l.c. provides tobacco and nicotine products to consumers in the Americas, Europe, the Asia-Pacific, the Middle East, Africa, and the United States. It offers vapour, heated, and modern oral nicotine products; combustible cigarettes; and traditional oral products, such as snus and moist snuff. The company provides its products under the Vuse, glo, Velo, Grizzly, Kodiak, Dunhill, Kent, Lucky Strike, Pall Mall, Rothmans, Newport, Natural American Spirit, and Camel brands. The company distributes its products to retail outlets. British American Tobacco p.l.c. was founded in 1902 and is based in London, the United Kingdom.

Full BTI Calculator →
📬

Get this ONCT vs BTI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ONCT vs SCHDONCT vs JEPIONCT vs OONCT vs KOONCT vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.